.Pharmacolibrary.Drugs.ATC.B.B02BX10 .Pharmacolibrary.Drugs.ATC.B.B02BX10| name: | Concizumab |
| ATC code: | B02BX10 | route: | subcutaneous |
| n-compartments | 2 |
Concizumab is a humanized monoclonal antibody that inhibits tissue factor pathway inhibitor (TFPI) and is developed for the treatment of hemophilia A and B with or without inhibitors. It is under clinical investigation and not yet widely approved or marketed.
Pharmacokinetic parameters were assessed in healthy subjects, adolescents, and patients with hemophilia A and B. Key phase 1/2/3 studies indicate subcutaneous administration with dose proportional increases in exposure.